Tavros Therapeutics Raises $7.5 Million in Oversubscribed Seed II Round
Funds to be used to continue developing proprietary platform to rapidly identify synthetically lethal interactions…
Month: September 2022
Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024
Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing…
Tavros Therapeutics Raises $7.5 Million in Oversubscribed Seed II Round
Funds to be used to continue developing proprietary platform to rapidly identify synthetically lethal interactions…
IN8bio to Present at Cantor Oncology & HemOnc Conference
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
Tavros Therapeutics Raises $7.5 Million in Oversubscribed Seed II Round
Funds to be used to continue developing proprietary platform to rapidly identify synthetically lethal interactions…
IN8bio to Present at Cantor Oncology & HemOnc Conference
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) — Opus Genetics, a patient-first gene…
IN8bio to Present at Cantor Oncology & HemOnc Conference
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) — Opus Genetics, a patient-first gene…
Mindset Pharma Provides Strategic Intellectual Property License to Cybin
Licensing Subset of Mindset’s Family 1 Intellectual Property Underscores Strength of Mindset’s Portfolio and Business…
Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) — Opus Genetics, a patient-first gene…
Mindset Pharma Provides Strategic Intellectual Property License to Cybin
Licensing Subset of Mindset’s Family 1 Intellectual Property Underscores Strength of Mindset’s Portfolio and Business…
Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November…
Mindset Pharma Provides Strategic Intellectual Property License to Cybin
Licensing Subset of Mindset’s Family 1 Intellectual Property Underscores Strength of Mindset’s Portfolio and Business…
Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November…
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage…
Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November…
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage…
Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen®
AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen® Tmax…
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage…